Entera Bio (NASDAQ:ENTX) Director Acquires $22,320.00 in Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Sean Ellis bought 18,000 shares of Entera Bio stock in a transaction on Monday, February 9th. The stock was acquired at an average price of $1.24 per share, for a total transaction of $22,320.00. Following the transaction, the director directly owned 178,098 shares of the company’s stock, valued at approximately $220,841.52. This trade represents a 11.24% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Entera Bio Stock Down 1.3%

Shares of Entera Bio stock opened at $1.50 on Friday. The firm has a market cap of $68.79 million, a PE ratio of -6.00 and a beta of 1.84. Entera Bio Ltd. has a 52 week low of $1.00 and a 52 week high of $3.22. The business’s fifty day simple moving average is $1.67 and its 200-day simple moving average is $2.02.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. As a group, equities analysts expect that Entera Bio Ltd. will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Entera Bio in a research report on Monday, February 9th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, December 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Entera Bio currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Entera Bio

Several institutional investors have recently modified their holdings of the business. Bessemer Group Inc. acquired a new stake in shares of Entera Bio in the second quarter valued at $268,000. Jane Street Group LLC grew its stake in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the period. HighTower Advisors LLC raised its position in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares in the last quarter. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.